Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents

Manavi, Mohammad Amin; Fathian Nasab, Mohammad Hosein; Mohammad Jafari, Razieh; Dehpour, Ahmad Reza

doi:10.1080/1120009x.2023.2300217

Cited by 7 publications

(2 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular toxicity is a rare adverse effect of bleomycin and may be expressed clinically as hypotension, pericarditis, acute substernal chest pain, coronary artery dis-ease, myocardial ischemia, myocardial infarction, and cerebral vascular accident, with an incidence of 1-3% [26,27].…”

Section: Bleomycinmentioning

confidence: 99%

“…The main cardiovascular side effects provoked by vincristine are myocardial ischemia and infarction, which tend to occur during or shortly after therapy and might, therefore, be related to coronary artery vasospasm as a result of cellular hypoxia, causing significant transitory impairment in the vasodilator and the contractile function, as well as temporary vascular damage [27].…”

Section: Vincristinementioning

confidence: 99%

See 1 more Smart Citation

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Mandala,

Lafara,

Kokkinovasilis

et al. 2024

Life

View full text Add to dashboard Cite

Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity’s definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.

show abstract

Section: Bleomycinmentioning

confidence: 99%

Section: Vincristinementioning

confidence: 99%

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Mandala,

Lafara,

Kokkinovasilis

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

Spermidine Exerts Protective Effects in Random-Pattern Skin Flap Survival in Rats: Possible Involvement of Inflammatory Cytokines, Nitric Oxide, and VEGF

Jouyban,

Mohammad Jafari,

Charkhpour

et al. 2024

Aesth Plast Surg

View full text Add to dashboard Cite

Synergistic strategies for cancer treatment: leveraging natural products, drug repurposing and molecular targets for integrated therapy

Mikkili,

Suluvoy,

Thathapudi

et al. 2024

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

Background Uncontrolled cell proliferation is a major cause of cancer development and progression. Inflammation along with inflammatory mediators and cells play a significant role in cancer. Cancer ranks in second in mortality rates, following cardiac diseases. Phytochemicals from medicinal plants offer a natural and effective approach for treating Inflammation and cancer. Main body of the abstract Animal studies provide evidence that phytochemicals present in food acts as antioxidants, anti-aging molecules, and health promoters, thereby extending lifespan. These natural compounds include quercetin, epicatechin, resveratrol, curcumin, kaempferol, vitamin C and carotenoids. However, clinical data on humans is still awaited. Conventional allopathic cancer therapies often have severe side effects. Recently, drug repurposing has emerged as an alternative strategy offering lower costs, shorter development times and the advantage of existing clinical data. The primary goal of drug repurposing is to discover new uses for approved or experimental drugs. Short conclusion The current review elucidates the side effects of synthetic drugs and the beneficial effects of phytochemicals and non-oncological drugs along with their mechanisms of action for treating cancer. Additionally, it highlights clinical trial data for various cancers focusing on molecular targets. By integrating natural products, drug repurposing and molecular targets, we can develop multifaceted therapies that maximize efficacy and minimize adverse effects. This integrated approach promises more personalized and effective treatments, improving patient outcomes and quality of life. Future research should identifying novel natural compounds, explore repurposing opportunities for existing drugs, and elucidate molecular targets for precise therapy. Additionally, clinical trials should be conducted to validate the efficacy and safety of these combined strategies in cancer patients. Graphical abstract

show abstract

Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents

Cited by 7 publications

References 203 publications

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Spermidine Exerts Protective Effects in Random-Pattern Skin Flap Survival in Rats: Possible Involvement of Inflammatory Cytokines, Nitric Oxide, and VEGF

Synergistic strategies for cancer treatment: leveraging natural products, drug repurposing and molecular targets for integrated therapy

Contact Info

Product

Resources

About